Today, heart attacks are diagnosed after the fact when symptoms have been physically overwhelming, and that is often too late for the people we love. With better cardiovascular disease (CVD) prevention technology, no one should die from a heart attack. CVDs represent a significant global health challenge, affecting many people worldwide and resulting in approximately 17.9 million deaths annually. CVD includes hypertension, atherosclerosis, coronary artery disease, and silent myocardial infarctions, which are occasionally mistaken for panic attacks or heartburn. Today's heart disease differs from those of the past few decades.
A Wall Street Journal article best summarizes the current need with a quote from Dr. Harlan Krumholz, a Yale University cardiologist and incoming editor-in-chief of the Journals of the American College of Cardiology:
"Heart experts say they need new tools and approaches because doctors also need 'more granular, more accurate, more timely digital health-care.'"
Current consumer health trackers are limited to PPG (Photoplethysmography) sensors and measure VO2 max, blood oxygen, heart rate, and heart rate variability. The current solutions lack accurate, granular digital health metrics. ViviScout's breakthrough technology is designed to offer real-time, non-invasive monitoring of many key risk factors for all types of users: busy professionals, athletes chasing peak performance, grandparents keeping up with their grandchildren, and everyone in between.
ViviScout's technology intends to detect heart attacks by looking for digital biomarkers for significant changes in your cardiovascular health. The company is undergoing preclinical animal studies on detecting heart attacks and is conducting clinical studies on continuous blood pressure monitoring at the big data scale of 100,000 blood pressure measurements a day from one individual. ViviScout's technology is being developed to understand the intricate details of your heart's performance.
ViviScout intends to sell an innovative consumer product designed to bridge the gap between at-home general fitness trackers and in-hospital advanced cardiovascular health monitoring. By utilizing a variety of artificial intelligence (AI) technologies, including large language models (LLMs), ViviScout has the potential to monitor an individual's cardiovascular health from the moment they wear it all the way into their 80s and beyond. This technology will be wrapped in an ultra-low profile luxury package.
The key differentiator being developed at ViviScout is the early detection and continuous monitoring of potential CVD. Traditional fitness trackers can struggle to offer detailed insights into cardiovascular health, often overlooking critical signs of underlying conditions. This gap in monitoring can lead to undiagnosed and untreated CVD, resulting in sudden heart attacks or other serious health risks in seemingly healthy individuals.
The future for ViviScout is very promising. Their future aspirations include extracting proprietary digital biomarkers that may reveal critical details about cardiovascular health. Some early examples include plaque levels, the volume of blood pumped by the heart, and continuous blood pressure. ViviScout's software can alert users to significant changes, such as a steady increase in plaque levels in your arteries or signs of a weakening heart muscle as you age from your twenties into your fifties.
Additionally, ViviScout may detect issues like heart blockages and valve malfunctions months before symptoms appear and are identified through traditional medical exams. This comprehensive monitoring system helps ensure that users receive early warnings to discuss with their doctors and take preventive measures to maintain their cardiovascular health. ViviScout is on a path to reshape preventive cardiology.
The total market size for just one of ViviScout's commercialization markets, the treatment and monitoring of hypertension, is approaching half a trillion dollars globally. ViviScout's SOM is estimated to be 4 billion dollars in the United States. The company has already achieved important milestones in testing prototypes and patent protection. The initial stage of their go-to-market strategy is estimated to bring in $10 million in revenue. The path to FDA approval is being investigated with several preclinical and clinical trials.
"We want to be able to create an early warning system for heart attacks and other cardiovascular diseases. Just being able to detect a heart attack in real-time is great, but what would be even better is if we could give you a 30-minute warning before the heart attack happens," says James Chen, the founder of ViviScout, a veteran of FDA regulations in medical devices and pharmaceuticals.
By providing continuous, real-time data and advanced analytics, ViviScout is working to empower individuals with the knowledge and tools to manage their cardiovascular health proactively. For ViviScout, the future of wearable technology is about extending health spans and saving lives. CVD is the current focus, and the ViviScout platform is being evaluated for future breakthroughs in the early detection of many other health indications, including but not limited to panic and anxiety attacks. To get involved, contact ViviScout at www.viviscout.com/contact.
With the appropriate FDA approval, it is important to understand that the data collected by ViviScout should only be interpreted by medical professionals.
Join the Conversation